

ARCHIVEL FARMA, S.L.

Our focus is on the discovery and early clinical development of novel biopharmaceutical agents for the prevention and treatment of tuberculosis (TB) and other diseases susceptible to immunomodulatory interventions

Our vision is to become a company respected and valued as a flexible and efficient quality provider of innovative products

Partnership with academic institutions, CROs, and other companies capable of further developing and launching our products is cornerstone in our business strategy

OWN MANUFACTURING FACILITIES GMP-compliant

Designed for the manufacture of injectable biological products under Biological Safety Level 3 and sterile conditions

RUTI®

**A novel poly-antigenic vaccine for the treatment of Latent TB Infection
A phase II Clinical Trial is ongoing and will finish on Q2-2011**

Current Treatment:

Latent TB infection is currently treated with antibiotics, usually isoniazid (INH), for a period of 6 to 9 months. Due to the **long duration**, up to 50% of the individuals abandon the treatment

The antibiotics currently used have also a potential for **hepatotoxicity** which requires regular monitoring of liver enzymes

Hence, current treatment options have **low effectiveness**

Our treatment proposition:

1 month INH +



Improved compliance
Lower risk of hepatotoxicity
Higher effectiveness
Reduced healthcare costs